SG10201914064QA - Anti-human 4-1 bb antibodies and use thereof - Google Patents

Anti-human 4-1 bb antibodies and use thereof

Info

Publication number
SG10201914064QA
SG10201914064QA SG10201914064QA SG10201914064QA SG10201914064QA SG 10201914064Q A SG10201914064Q A SG 10201914064QA SG 10201914064Q A SG10201914064Q A SG 10201914064QA SG 10201914064Q A SG10201914064Q A SG 10201914064QA SG 10201914064Q A SG10201914064Q A SG 10201914064QA
Authority
SG
Singapore
Prior art keywords
antibodies
human
Prior art date
Application number
SG10201914064QA
Inventor
Byoung S Kwon
Seoung-Joo Lee
Young Ho Kim
Ho-Sik Oh
Joong Won Lee
Original Assignee
Eutilex Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eutilex Co Ltd filed Critical Eutilex Co Ltd
Publication of SG10201914064QA publication Critical patent/SG10201914064QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
SG10201914064QA 2017-01-06 2018-01-05 Anti-human 4-1 bb antibodies and use thereof SG10201914064QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762443281P 2017-01-06 2017-01-06

Publications (1)

Publication Number Publication Date
SG10201914064QA true SG10201914064QA (en) 2020-03-30

Family

ID=62791389

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201903021WA SG11201903021WA (en) 2017-01-06 2018-01-05 Anti-human 4-1 bb antibodies and use thereof
SG10201914064QA SG10201914064QA (en) 2017-01-06 2018-01-05 Anti-human 4-1 bb antibodies and use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201903021WA SG11201903021WA (en) 2017-01-06 2018-01-05 Anti-human 4-1 bb antibodies and use thereof

Country Status (13)

Country Link
US (4) US10174122B2 (en)
EP (2) EP4032911A1 (en)
JP (2) JP6609724B1 (en)
KR (2) KR102427192B1 (en)
CN (2) CN112210010B (en)
AU (3) AU2018206015B2 (en)
BR (1) BR112019007714B1 (en)
CA (1) CA3039772C (en)
ES (1) ES2905890T3 (en)
MX (1) MX2019004692A (en)
RU (1) RU2725811C1 (en)
SG (2) SG11201903021WA (en)
WO (1) WO2018127787A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101503341B1 (en) 2014-03-12 2015-03-18 국립암센터 Methods for isolation and proliferation of autologous cancer antigen-specific CD8+ T cells
MX2019004692A (en) 2017-01-06 2019-11-08 Eutilex Co Ltd Anti-human 4-1 bb antibodies and use thereof.
BR112019017241A2 (en) 2017-04-13 2020-04-14 Agenus Inc anti-cd137 antibodies and methods of using them
SG10201913147WA (en) 2017-07-11 2020-02-27 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. Anti-cd137 molecules and use thereof
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
WO2019100052A2 (en) 2017-11-20 2019-05-23 Compass Therapeutics Llc Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
AU2019340530A1 (en) * 2018-09-12 2021-03-11 Eucure (Beijing) Biopharma Co., Ltd Anti-TNFRSF9 antibodies and uses thereof
CN112867733B (en) * 2018-10-19 2023-01-06 苏州丁孚靶点生物技术有限公司 anti-CD 137 antibodies and uses thereof
SG11202105152YA (en) * 2018-11-30 2021-06-29 Abl Bio Inc Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
EP3958908A1 (en) 2019-04-24 2022-03-02 Heidelberg Pharma Research GmbH Amatoxin antibody-drug conjugates and uses thereof
WO2021132746A1 (en) * 2019-12-24 2021-07-01 Abl Bio, Inc. Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof
CN113045657B (en) * 2019-12-26 2022-06-07 杭州济元基因科技有限公司 Humanized anti-human BCMA monoclonal antibody and CAR-T cell thereof
TW202144395A (en) * 2020-02-12 2021-12-01 日商中外製藥股份有限公司 Anti-CD137 antigen-binding molecule for use in cancer treatment
JP2023516945A (en) * 2020-02-28 2023-04-21 上海復宏漢霖生物技術股▲フン▼有限公司 Anti-CD137 constructs and uses thereof
JPWO2021251459A1 (en) * 2020-06-11 2021-12-16
KR20230042524A (en) * 2020-08-07 2023-03-28 주식회사 유틸렉스 Anti-HER2 / Anti-4-1BB Bispecific Antibodies and Uses Thereof
CN114075287B (en) * 2020-08-18 2023-07-21 湖南远泰生物技术有限公司 Humanized BCMA antibodies and BCMA-CAR-T cells
JP2023541853A (en) * 2020-09-08 2023-10-04 ユーティレックス カンパニー リミテッド PD-1 polypeptide variants
WO2022149050A2 (en) * 2021-01-11 2022-07-14 Kwon Byoung S Bispecific epitope binding protein comprising anti-4-1bb antibody and pd-1 protein or fragments thereof and use thereof
CA3230481A1 (en) * 2021-08-31 2023-03-09 LaNova Medicines Limited Anti-4-1bb nanobodies
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0359096B1 (en) 1988-09-15 1997-11-05 The Trustees Of Columbia University In The City Of New York Antibodies having modified carbohydrate content and methods of preparation and use
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
EP1007569B1 (en) 1997-02-11 2009-04-08 Immunomedics, Inc. Stimulation of an immune response with antibodies labeled with the alpha-galactosyl epitope
WO1999024069A1 (en) 1997-11-10 1999-05-20 Mochida Pharmaceutical Co., Ltd. Preventives and remedies for diffuse lung diseases
DK1071700T3 (en) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glycosylation modification of antibodies to enhance antibody-dependent cellular cytotoxicity
US7030211B1 (en) 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
KR20000034847A (en) * 1998-11-17 2000-06-26 성재갑 Humanized Antibody Specific for Human 4-1BB Molecule and Pharmaceutical Composition Comprising Same
DK2270150T4 (en) 1999-04-09 2019-08-26 Kyowa Hakko Kirin Co Ltd PROCEDURE TO CONTROL THE ACTIVITY OF IMMUNOLOGICAL FUNCTIONAL MOLECULE.
CA2388245C (en) 1999-10-19 2012-01-10 Tatsuya Ogawa The use of serum-free adapted rat cells for producing heterologous polypeptides
DE60043158D1 (en) 1999-11-18 2009-11-26 Pharmexa Inc HETEROKLITIC ANALOGUE OF CLASS I EPITOPES
US20040146519A1 (en) 1999-12-10 2004-07-29 John Fikes Inducing cellular immune responses to carcinoembryonic antigen using peptide and nucleic acid compositions
ES2353347T3 (en) 2000-08-21 2011-03-01 Apitope Technology (Bristol) Limited PEPTIDE
JPWO2002030954A1 (en) 2000-10-06 2004-02-19 協和醗酵工業株式会社 Methods for purifying antibodies
PL218428B1 (en) 2000-10-06 2014-12-31 Kyowa Hakko Kogyo Kk Cells producing antibody compositions
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
KR100468321B1 (en) 2001-02-08 2005-01-27 학교법인 울산공업학원 Polypeptides for treatment of cancers and AIDS
EP1390064A4 (en) 2001-03-09 2006-10-18 Baylor Res Inst Method of treating malignancies through induction of blood immune responses
EP1434596B1 (en) 2001-10-09 2009-07-08 Mayo Foundation For Medical Education And Research Enhancement of immune responses by agonist 4-1bb-antibodies
KR100988949B1 (en) 2001-10-25 2010-10-20 제넨테크, 인크. Glycoprotein compositions
KR100500286B1 (en) 2002-07-02 2005-07-11 현대모비스 주식회사 Lamp switch apparatus for a vehicle
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
KR100500283B1 (en) 2003-03-25 2005-07-11 이뮤노믹스 주식회사 Humanized Monoclonal Polypeptide Specific for Human 4-1BB Molecule and Pharmaceutical Composition Comprising Same
CA2525519A1 (en) 2003-05-08 2004-12-02 Xcyte Therapies, Inc. Generation and isolation of antigen-specific t cells
US20050011582A1 (en) 2003-06-06 2005-01-20 Haug Jeffrey S. Fluid delivery system for a flow cytometer
AR046094A1 (en) * 2003-10-10 2005-11-23 Bristol Myers Squibb Co COMPLETELY HUMAN ANTIBODIES AGAINST HUMAN 4-1BB
US7288638B2 (en) * 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
KR100694508B1 (en) * 2005-05-24 2007-03-13 울산대학교 산학협력단 A composition comprising HBBK4 antibody for the treatment of cancer and the immunotherapic method for treating cancer using thereby
CA2651328A1 (en) 2006-05-05 2007-11-15 Opexa Therapeutics T-cell vaccine
KR100882445B1 (en) 2007-03-16 2009-02-09 울산대학교 산학협력단 A method for isolating and expanding autologous antigen-specific CD8+ T cells using an anti-4-1BB antibody
KR101103603B1 (en) 2008-07-25 2012-01-09 국립암센터 A method for isolating and expanding antigen-specific CD8+ T cells using an 4-1BB ligand pentamer protein
EP2172211B1 (en) 2008-10-01 2014-12-03 Immatics Biotechnologies GmbH Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
KR20100043130A (en) 2008-10-18 2010-04-28 울산대학교 산학협력단 Composition for activation and proliferation of cd8 t-cell
US10817851B2 (en) 2009-12-23 2020-10-27 Aristocrat Technologies Australia Pty Limited System and method for cashless gaming
RU2551963C2 (en) * 2010-09-09 2015-06-10 Пфайзер Инк. Molecules binding to 4-1bb
CN108676069A (en) 2012-01-13 2018-10-19 纪念斯隆凯特林癌症中心 Immunogenicity WT-1 peptides and its application method
ES2783026T3 (en) * 2014-02-04 2020-09-16 Pfizer Combination of a PD-1 antagonist and a 4-1BB agonist for the treatment of cancer
KR101503341B1 (en) 2014-03-12 2015-03-18 국립암센터 Methods for isolation and proliferation of autologous cancer antigen-specific CD8+ T cells
KR20170017916A (en) * 2014-05-13 2017-02-15 추가이 세이야쿠 가부시키가이샤 T cell-redirected antigen-binding molecule for cells having immunosuppression function
RU2016146993A (en) 2014-05-21 2018-06-21 Пфайзер Инк. Combination of anti-CCR4 antibody and 4-1BB agonist for cancer treatment
US20170247455A1 (en) * 2014-08-22 2017-08-31 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
US10259881B2 (en) * 2015-02-22 2019-04-16 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD137
JP6876629B2 (en) * 2015-06-16 2021-05-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ PD-L1 antagonist combination therapy
WO2017205745A1 (en) * 2016-05-27 2017-11-30 Abbvie Biotherapeutics Inc. Anti-4-1bb antibodies and their uses
GB201619648D0 (en) * 2016-11-21 2017-01-04 Alligator Bioscience Ab Novel antibodies and uses thereof
MX2019004692A (en) 2017-01-06 2019-11-08 Eutilex Co Ltd Anti-human 4-1 bb antibodies and use thereof.
JP2021505168A (en) 2017-12-08 2021-02-18 ジュノー セラピューティクス インコーポレイテッド Methods for Producing Manipulated T Cell Compositions
KR20210042142A (en) 2018-08-10 2021-04-16 주식회사 유틸렉스 Preparation and cryopreservation method of cancer antigen-specific CD8+ T cells

Also Published As

Publication number Publication date
JP2020036595A (en) 2020-03-12
BR112019007714A2 (en) 2019-07-09
KR20200029618A (en) 2020-03-18
NZ753036A (en) 2020-10-30
CA3039772C (en) 2020-08-25
KR102427192B1 (en) 2022-07-29
EP3523332B1 (en) 2021-12-29
MX2019004692A (en) 2019-11-08
CN110392696A (en) 2019-10-29
RU2020120077A (en) 2020-12-03
AU2019204847B2 (en) 2021-05-20
AU2019204847A1 (en) 2019-08-01
AU2018206015A1 (en) 2019-05-16
US20180258177A1 (en) 2018-09-13
US20210214455A1 (en) 2021-07-15
KR102089072B1 (en) 2020-03-17
US10774151B2 (en) 2020-09-15
AU2021202474A1 (en) 2021-05-20
RU2020120077A3 (en) 2022-02-04
US10174122B2 (en) 2019-01-08
AU2018206015B2 (en) 2019-05-30
CN112210010B (en) 2023-12-05
JP6609724B1 (en) 2019-11-20
JP7153626B2 (en) 2022-10-14
US10919972B2 (en) 2021-02-16
CN110392696B (en) 2020-09-11
ES2905890T3 (en) 2022-04-12
CA3039772A1 (en) 2018-07-12
EP3523332A1 (en) 2019-08-14
JP2020503245A (en) 2020-01-30
WO2018127787A1 (en) 2018-07-12
RU2725811C1 (en) 2020-07-06
EP4032911A1 (en) 2022-07-27
US11859004B2 (en) 2024-01-02
KR20190095919A (en) 2019-08-16
US20200172626A1 (en) 2020-06-04
CN112210010A (en) 2021-01-12
SG11201903021WA (en) 2019-05-30
US20190071510A1 (en) 2019-03-07
BR112019007714B1 (en) 2022-01-18
EP3523332A4 (en) 2019-10-09

Similar Documents

Publication Publication Date Title
SG10201914064QA (en) Anti-human 4-1 bb antibodies and use thereof
IL268206A (en) Bcma-targeting antibody and use thereof
IL262240A (en) Anti-human vista antibodies and use thereof
IL276950A (en) Anti-cd73 antibodies and uses thereof
HUE058975T2 (en) Anti-cd73 antibodies and uses thereof
SG10201912199XA (en) Anti-tim-3 antibodies and use thereof
IL282968A (en) Anti-nkg2a antibodies and uses thereof
EP3541840C0 (en) Anti-hla-g antibodies and use thereof
ZA201701920B (en) Anti-human il-17 monoclonal antibodies and use thereof
SG11202105885WA (en) Anti-claudin antibodies and uses thereof
ZA202006066B (en) Anti-hla-g antibodies and use thereof
IL275826A (en) Anti-mct1 antibodies and uses thereof
IL281297A (en) Anti-npr1 antibodies and uses thereof
SG11202009772PA (en) Anti-dll3 antibodies and uses thereof
ZA201807132B (en) Humanized anti-basigin antibodies and the use thereof
SG11202009625WA (en) Anti-trem-1 antibodies and uses thereof
IL280321A (en) Anti-cxcr2 antibodies and uses thereof
IL277330A (en) Anti-il-27 antibodies and uses thereof
IL282707A (en) Anti-tim-3 antibodies and their use
IL282708A (en) Anti-tim-3 antibodies and their use
IL283875A (en) Anti-il-27 antibodies and uses thereof
IL277075A (en) Anti-phf-tau antibodies and uses thereof
IL276548A (en) Bcma-binding antibodies and uses thereof
GB201712032D0 (en) Antibodies and uses thereof
IL283926A (en) Anti-alpha-synuclein antibodies and uses thereof